DYADIC AND ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH COLLABORATE TO TACKLE BIO-THREATS AND EMERGING DISEASE SOLUTIONS
Jupiter, Fla. and Nes-Ziona, Israel, Feb. 23, 2024 - Dyadic International, Inc. (NASDAQ: DYAI), a renowned global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction, has announced an expanded collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm, Life Science Research Israel (LSRI). This partnership aims to leverage Dyadic’s expertise in microbial platforms along with IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats.
The COVID-19 pandemic has highlighted the need for collaborative efforts between global organizations to combat emerging diseases and potential bio-threats. Recognizing this urgency, Dyadic and the IIBR are joining forces to focus their combined expertise and resources on researching, developing, and producing effective treatments and vaccines.
Dyadic’s microbial platforms offer flexible scale protein bioproduction capabilities, enabling the rapid and cost-effective production of proteins essential for the development of therapeutics and vaccines. By harnessing these platforms, the collaboration aims to expedite the development processes and overcome the challenges associated with scaling up production.
On the other hand, the IIBR brings to the table its extensive experience and knowledge in antibodies and antigens discovery. IIBR’s expertise in understanding the molecular mechanisms that lead to the emergence of diseases will complement Dyadic’s strength in bioproduction. The collaboration between the two organizations will pave the way for the identification, development, and production of innovative solutions to address emerging health challenges across the globe.
While the framework of this collaboration is currently non-binding, both parties are committed to working together towards developing a binding agreement. Once established, this agreement will ensure that the solutions developed through this collaboration can be efficiently commercialized through out-licensing initiatives.
By combining their complementary capabilities, Dyadic and IIBR aspire to make substantial advancements in the fight against emerging diseases and potential bio-threats. This collaboration aims to foster a synergy that will fast-track the development and manufacturing processes, ultimately resulting in the escalation of effective treatment and vaccine availability to combat global health challenges.
Dyadic is excited to expand its collaboration with the Israel Institute for Biological Research and its commercial arm, Life Science Research Israel. We believe that by combining our unique strengths, we can make significant strides towards addressing emerging diseases and bio-threats, said Mark Emalfarb, Dyadic’s CEO. We look forward to leveraging our microbial platforms alongside IIBR’s discovery capabilities to develop innovative solutions for the benefit of global health.
Dr. Shmuel Yitzhaki, Director-General of the Israel Institute for Biological Research, expressed his enthusiasm for the collaboration, stating, We are delighted to advance our partnership with Dyadic and utilize their state-of-the-art bioproduction capabilities. By bringing together our respective expertise, we aim to enhance our ability to develop and produce effective treatments and vaccines against emerging diseases and bio-threats. This collaboration holds tremendous promise for the future of global health.
The Dyadic and IIBR collaboration is expected to drive groundbreaking advancements in the field of bioproduction and exploration of potential solutions for emerging diseases. As the binding agreement is entered into and the collaboration progresses, the exciting potential for improved global health outcomes through innovative treatments and vaccines becomes even more evident.
Comments